The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\[18F\] FDG) and fluorine-18 Displacement Per Atom (\[18F\]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.
Age between 40-85 years old.
A diagnosis of IPF that fulfills American Thoracic Society (ATS) / European Respiratory Society (ERS) 2018 consensus criteria within 5 years.
Ability and willingness to give informed consent and adhere to study requirements.
Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) >0.70.
Acute exacerbation of IPF within <30 days
Diagnosis of Diabetes Mellitus (Type 1 or Type 2).
Diagnoses of current infection by clinical or microbial assessments.
Treatment for >14 days within the preceding month with >20 mg. prednisone (or equivalent) or any treatment during the last month with a cellular immunosuppressant.